CN101880651A - Preparation method of Muscovy duck parvo novel vaccines - Google Patents
Preparation method of Muscovy duck parvo novel vaccines Download PDFInfo
- Publication number
- CN101880651A CN101880651A CN 201010215818 CN201010215818A CN101880651A CN 101880651 A CN101880651 A CN 101880651A CN 201010215818 CN201010215818 CN 201010215818 CN 201010215818 A CN201010215818 A CN 201010215818A CN 101880651 A CN101880651 A CN 101880651A
- Authority
- CN
- China
- Prior art keywords
- duck
- strain
- muscovy duck
- muscovy
- parvovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to a preparation method of Muscovy duck parvo novel vaccines, which comprises the following steps of: using Muscovy duck parvovirus attenuated virus P1 strain (MPV-P1 strain with a preservation number of CCTCC NO:V201013) and Muscovy duck origin goose parvovirus attenuated virus D strain ( GPV-D strain with a preservation number of CCTCC NO:V201014) as seed viruses; proliferating viruses by applying the muscovy duck embryone fibroblast spinner culture technology to obtain cell toxic liquids; mixing the cell toxic liquids according to the proper proportion and freezing a dry protective agent to freeze and dry to research safe and effective Muscovy duck parvo novel vaccines. The young Muscovy ducks are inoculated once so as to prevent and control the Muscovy duck parvovirus infection and the Muscovy duck gosling blast dieases at the same time, thereby the stress reaction of the Muscovy ducks caused by immunization for many times is solved. The invention is suitable for scale production under the GMP (Good Manufacturing Practices) condition, and saves the production cost of the vaccines.
Description
Technical field
The present invention relates to the preparation method of Muscovy duck parvo novel vaccines.
Background technology
Kind duck parvovirus (being commonly called as " three weeks are sick ") is the 1-3 kind duck in age in week at first found at our province in 1987, and to rush down be a kind of new eqpidemic disease of clinical symptom to breathe heavily.This disease is mainly encroached on the young bird kind duck of 7-21 age in days, sickness rate 27-62% and case fatality rate 22-43%, and the duck major part of recovering becomes stiff duck, already causes very large economy loss for kind duck.Aspect this disease pathogen, diagnosis and study on prevention, I all occupy the top standard of international similar research.We at first separate, have identified a kind duck parvovirus (MPV) at home and abroad, confirm that MPV is kind cause of disease of duck parvovirus, are the newcomers that the Parvoviridae parvovirus belongs to, and have enriched the animal virology content.Set up on this basis and prepared 5 strain monoclonal antibodies, use a wherein strain monoclonal antibody sensitization polystyrene latex, take the lead in having set up latex agglutination (LPA) and agglutination inhibition test (LPAI) detection virus and antibody at home and abroad; Utilize biotechnology to select simultaneously and meet the low virulent strain that the manufacturing living vaccine is used, the vaccine of preparation can effectively prevent a kind duck parvovirus." kind duck parvovirus disease live-vaccine " and " kind duck parvovirus diagnostic reagent " obtained the new veterinary drug certificate of a national class respectively in 2000.
Kind duck gosling blast is to have raised district's outbreak of epidemic kind duck on ground such as Putian, Fujian Province, Fuqing since 1997, and all there is generation in each foster duck area, the whole nation at present.Young clinically kind duck takes place to come off with diarrhoea, intestinal mucosa, and to form embolism be feature, sickness rate 50-70%, case fatality rate 40-65%.Use various antibiotic, kind duck parvovirus vaccine and the high immunity yolk antibody etc. all can not disease controlling, the provisions duck be already caused than large economy and loses.Be effectively anti-this disease of system, we have carried out cause of disease, diagnosis and study on prevention: from 1997 should disease Fujian Province kind duck raise the district popular since, we successively are separated to 8 strains kind duck source goose parvovirus from morbidity kind duck internal organs, and carried out comprehensive and systematic evaluation, confirm that this virus is kind duck gosling blast virus, clinically should disease normal and kind duck parvovirus polyinfection, very harmful, artificial challenge or find all that clinically its M ﹠ M all is higher than a kind duck parvovirus.On this basis, our seed selection becomes kind duck gosling blast virocyte to adapt to low virulent strain and is developed into a kind duck gosling blast attenuated vaccine, can effectively prevent this disease.
Kind duck parvovirus and kind duck gosling blast all are important transmissible diseases of kind duck, use vaccine and can effectively prevent the generation of this two disease, in order to reduce manpower and materials and to reduce because of immunization repeatedly the distress that the duck group causes is reacted, we develop Muscovy duck parvo novel vaccines again, and young kind of duck immunity of 1-2 age in days can prevent kind duck parvovirus and kind duck gosling blast 1 time throughout one's life.
Summary of the invention
The purpose of this invention is to provide the preparation method of Muscovy duck parvo novel vaccines, the present invention is achieved by the following technical solution:
A kind ofly derive from the weak malicious P1 strain (MPV-P1 strain) of the exquisite weak kind duck parvovirus of people, be deposited in CCTCC, June 2 2010 preservation day, deposit number: CCTCCNO:V201013.
A kind ofly derive from the weak malicious D strain (GPV-D strain) of the exquisite weak kind duck source goose parvovirus of people, be deposited in CCTCC, June 2 2010 preservation day, deposit number: CCTCC NO:V201014.
Malicious D strain a little less than malicious P1 strain a little less than the above-mentioned kind duck parvovirus and kind duck source goose parvovirus is applied to prepare Muscovy duck parvo novel vaccines.
The present invention with kind duck parvovirus a little less than the weak malicious D strain (GPV-D strain) of malicious P1 strain (MPV-P1 strain) and kind duck source goose parvovirus serve as kind malicious; use kind DEF rolling bottle culture technique virus of proliferation; the harvested cell venom; by adding the lyophilized vaccine lyophilize after the suitable proportion mixing; be developed into genetic stability, security is good, immunogenicity is strong and cost is low Muscovy duck parvo novel vaccines, reach the purpose that once inoculation could prevent and control two kinds of eqpidemic diseases simultaneously.The present invention is suitable for scale operation Muscovy duck parvo novel vaccines under the GMP condition.
Embodiment
The present invention is further described below in conjunction with specific embodiment.(but not being limitation of the present invention).
Derive from the weak malicious P1 strain (MPV-P1 strain) of the exquisite weak kind duck parvovirus of people, be to utilize kind duck embryo and kind DEF alternately to go down to posterity etc. to form a little less than the biotechnology artificially breeding causes, lost pathogenic to the young kind duck of an age in days, and have following characteristic (1) virus titer: the MPV-P1 strain is inoculated 12 ages in days kind duck embryo, its ELD through allantoic cavity
50Answer 〉=10
-4.5/ 0.1ml; To a kind duck embryo fibroblast monolayer cell TCID
50〉=10
-5.0/ 0.1ml; (2) security: with young kind duck 10 plumages of the healthy susceptible of 1 age in days, 0.2 milliliter of every plumage leg muscle injection seed culture of viruses stoste was observed 20 days, should all survive; (3) immunogenicity: the healthy responsive young kind duck of an age in days, 0.2 milliliter of leg muscle injection, its minimum immunity amount is 100TCID
50/ 0.2ml; (4) virus multiplication: select MDEF multiplication culture MPV-P1 for use, inoculum size is 4～5 days for the time that 1%, 37 ℃ of rotating and culturing to cytopathy of cultivating liquid measure reaches more than 75% synchronously.The MPV-P1 strain be deposited in Chinese typical culture collection center (or be called for short: CCTCC), June 2 2010 preservation day, deposit number CCTCCNO:V201013.
Derive from the weak malicious D strain (GPV-D strain) of the exquisite weak kind duck source goose parvovirus of people, be to utilize a kind DEF variable to go down to posterity alternately to form a little less than seed selection causes, lost pathogenic to the young kind duck of an age in days, and had following characteristic (1) virus titer: the GPV-D strain is to kind duck embryo fibroblast monolayer cell TCID50 〉=10
-4.5/ 0.1ml; LPA tires and reaches 2
3(2) security: with young kind duck 10 plumages of the healthy susceptible of 1 age in days, 0.2 milliliter of every plumage leg muscle injection seed culture of viruses stoste was observed 20 days, should all survive; (3) immunogenicity: the healthy responsive young kind duck of an age in days, 0.2 milliliter of leg muscle injection, its minimum immunity amount is 300TCID
50/ 0.2ml; (4) virus multiplication: select MDEF multiplication culture GPV-D for use; Inoculum size is 4～5 days for the time that 1%, 37 ℃ of rotating and culturing to cytopathy of cultivating liquid measure reaches more than 75% synchronously.The GPV-D strain is deposited in CCTCC, June 2 2010 preservation day, deposit number CCTCC NO:V201014.
Malicious D strain a little less than malicious P1 strain a little less than the above-mentioned kind duck parvovirus and kind duck source goose parvovirus is applied to the preparation method of Muscovy duck parvo novel vaccines:
(1) MPV-P1 strain propagation, by the 1% synchronous inoculation kind DEF (MDEF) of cultivating liquid measure, 37 ℃ of rotating and culturing to cytopathies reach more than 75%, results MPV-P1 cell toxicant with MPV-P1 strain kind poison.
(2) GPV-D strain propagation, by the 1% synchronous inoculation kind DEF (MDEF) of cultivating liquid measure, 37 ℃ of rotating and culturing to cytopathies reach more than 75%, results GPV-D cell toxicant with GPV-D strain kind poison.
(3) viral level TCID
50Measure, MPV-P1 and GPV-D are to a kind duck embryo fibroblast monolayer cell TCID50 difference 〉=10
-4.5/ 0.1ml and 〉=10
-4.0When/0.1ml is above, can be used for preparing vaccine.(4) vaccine preparation adds the lyophilized vaccine lyophilize with MPV-P1 and GPV-D after by 1: 1～1.5 mixed and forms.
How reducing production costs and improving immune effect is the gordian technique that the present invention will solve, and for this reason, the present invention further takes following measure:
(1) cell culture fluid: get 0.5% newborn Chinese liquid and add equivalent DMEM liquid, include each 100 units/ml of 3% calf serum, penicillin and Streptomycin sulphate, and with 7.5%NaHCO
3Accent pH is 7.4-7.6.
(2) kind DEF preparation: get and hatch well-developed kind of duck embryo of 17 ages in days, on the ovoscopy lamp, use the stroke discharge chamber.Place on the incubator tray, earlier use 75% alcohol disinfecting eggshell air chamber again with 2% tincture of iodine, aseptic taking-up embryo, decaptitate, four limbs and internal organ, put into the glassware of sterilization, use Hank ' s liquid washing idiosome, be cut into 2～3mm with the scissors of sterilizing and organize fritter, pour in the sterilization triangle digestion bottle, use Hank ' s liquid to wash again 2～3 times, 0.25% pancreatin (each embryo 8～10ml) that adds 37 ℃, be placed on that stirring at low speed left standstill 5 minutes after 30 minutes on constant temperature (37 ℃) magnetic stirring apparatus, tissue block is avaled, the upper strata cell suspension is poured in the 500ml sterilization vial, and vial places ice bath.Tissue block in the digestion bottle adds 0.25% an amount of pancreatin again, the samely repeats to digest 3～4 times, when tissue block is flocculence, promptly stops digestion.Cell suspension in packing 250～500ml sterilization centrifugal bottle (pipe), in centrifugal 15～20 minutes kinds of 4 ℃～8 ℃ low speed (800～1000 rev/mins), is abandoned supernatant liquor after filtering with 4 layers of sterile gauze.The cell precipitation piece of each centrifugal bottle, the nutrient solution that contains 5% calf serum with 3～5ml dispels, collect in each centrifugal bottle (pipe) spissated cell suspension in the 100ml vial, count every milliliter and contain cell count, with cell culture fluid the concentrating cells suspension is diluted to every milliliter and contains 150～1,800,000 viable cell.Standby.
(3) virus multiplication: synchronous respectively inoculation MPV-P1 of kind DEF and GPV-D kind poison, inoculum size is 1% of the cultivation liquid measure, the rearmounted 37 ℃ of rotating and culturing of mixing, rotating speed is per hour 9～11 commentaries on classics.Every day, observation of cell was 2 times, when pathology (cytopathy is that the cell refractivity strengthens, and the cell circle contracts) appears in 75% above cell, culturing bottle is put-20 ℃ frozen.
(4) vaccine immunity is learned index determining
4.1 steriling test: undertaken by existing " People's Republic of China's veterinary drug allusion quotation " appendix, answer asepsis growth.
4.2 viral level is measured: carry out on MDEF individual layer 96 orifice plates respectively, every extent of dilution connects 4 holes, and the 0.1ML/ hole is put under CO26.0,37 ℃ of conditions and cultivated, and observes 7 days, calculates TCID
50MPV-P1 answers 〉=10
5.5TCID
50/ ml and GPV-D answer 〉=10
5.0TCID
50/ ml.
4.3 safety verification: with young kind duck 10 plumages of the healthy susceptible of 1 age in days, the vaccine of 10 times of amounts of every plumage leg muscle injection was observed 20 days, and the inoculation duck there is no diet desires and mental anomaly, and it is good to grow, all survivals.
4.4 efficacy test: as known from Table 1, the young kind duck leg flesh of an age in days susceptible is inoculated 1 plumage part vaccine, and in inoculating back 7 days together with not immune control group blood sampling separation of serum, measures for the LPAI antibody titer; Attack MPV and GPV poison by force simultaneously respectively, every group 10 plumage.The result shows: immune duck all can be resisted the attack with the source strength poison, and protection ratio reaches 100% and 87.5% respectively; Attack simultaneously before the poison that MPV-LPAI antibody and GPV-LPAI antibody reach 2 respectively in the immune duck serum
-2.2With 2
-2.3, and the contrast duck is 2
0.6Below.
After the young kind pest of duck seedling immunity of table 1 age in days protection ratio with the source strength poison is measured
4.5 immune generation phase and immune duration are measured: as known from Table 2, back 7 days LPAI antibody horizontals of immunity are all 2
2.0More than, and can resist strong virus attack, and continue to i.e. 87 ages in days of back 80 days of immunity always, met or exceeded a kind duck and delivered age in days for sale this moment.The result shows that young kind of duck immunity of an age in days can protect for 1 time throughout one's life, means that also 1 immunization can prevent kind a duck parvovirus and a gosling blast simultaneously, not only reduces manpower and materials, also reduces the stress reaction that causes because of immunization repeatedly.
Antibody horizontal dynamic change in the serum after the young kind pest of duck seedling immunity of table 2 age in days
4.6 behind the vaccine immunity anti-MPV LPAI antibody horizontal with attack poison protection dependency: as known from Table 3, measured anti-MPV LPAI antibody titer in 7 days behind the young kind duck immunization vaccine of 1 age in days, attack MPV poison by force simultaneously.Antibody titer is 2 as a result
-1More than, it is 100% antibody titer＜2 that MPV is attacked malicious protection ratio
-1, its sickness rate 62.5%, mortality ratio 33.3% proves that LPAI tires and protection is proportionate.Simultaneously, measure the MPV antibody titer with the LPAI method and can replace the method for vaccine potency check with strong virus attack, both easy, can prevent strong poison diffusion again.
Table 3 vaccine immunity is injected tire the * that concerns with protection of anti-MPV LPAI in back 7 days kinds of duck serum
| LPAI tires | Morbidity number/attack malicious number (plumage) | Death toll/attack malicious number (plumage) | Sickness rate (%) | Mortality ratio (%) |
| ??＜2 -1# | ??30/48 | ??16/48 | ??62.5 | ??33.3 |
| ??2 -1 | ??0/30 | ??0/30 | ??0 | ??0 |
| ??2 -2 | ??0/25 | ??0/25 | ??0 | ??0 |
4.7 behind the vaccine immunity anti-GPV LPAI antibody horizontal with attack poison protection dependency: as known from Table 4, measured anti-GPV LPAI antibody titer in 7 days behind the young kind duck immunization vaccine of 1 age in days, attack GPV poison by force simultaneously.Antibody titer is 2 as a result
-2More than, it is 100% that GPV is attacked malicious protection ratio; Antibody titer is 2
-1, its sickness rate 13%, mortality ratio 0; Antibody titer＜2
-1, its sickness rate 70%, mortality ratio 35%; Proof LPAI tires and protection is proportionate.Simultaneously, measure the GPV antibody titer with the LPAI method and can replace the method for vaccine potency check with strong virus attack, both easy, can prevent strong poison diffusion again.
Table 4 vaccine immunity is injected tire the * that concerns with protection of anti-GPV LPAI in back 7 days kinds of duck serum
| LPAI tires | Morbidity number/attack malicious number (plumage) | Death toll/attack malicious number (plumage) | Sickness rate (%) | Mortality ratio (%) |
| ??＜2 -1# | ??14/20 | ??7/20 | ??70％ | ??35％ |
| LPAI tires | Morbidity number/attack malicious number (plumage) | Death toll/attack malicious number (plumage) | Sickness rate (%) | Mortality ratio (%) |
| ??2 -1 | ??3/23 | ??0/23 | ??13％ | ??0 |
| ??2 -2 | ??0/20 | ??0/20 | ??0 | ??0 |
4.8 clinical application effect evaluation: be total to the young kind duck of immunization plumage more than 5000 part one age in days in test duck field, tracing observation 20d does not see that untoward reaction appears in immune duck; And the immune group surviving rate reaches more than 95%, apparently higher than control group (surviving rate 68%).Further this vaccine safety of proof, effective can be used for preventing clinically kind a duck parvovirus and a gosling blast.
Claims (3)
1. derive from the weak malicious P1 strain of the exquisite weak kind duck parvovirus of people, be deposited in CCTCC, June 2 2010 preservation day, deposit number: CCTCC NO:V201013.
2. derive from the weak malicious D strain of the exquisite weak kind duck source goose parvovirus of people, be deposited in CCTCC, June 2 2010 preservation day, deposit number: CCTCC NO:V201014.
3. the application on the preparation Muscovy duck parvo novel vaccines with weak malicious P1 strain of described kind of duck parvovirus of claim 1 and the weak malicious D strain of described kind of duck source of claim 2 goose parvovirus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010215818 CN101880651B (en) | 2010-07-01 | 2010-07-01 | Preparation method of Muscovy duck parvo novel vaccines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010215818 CN101880651B (en) | 2010-07-01 | 2010-07-01 | Preparation method of Muscovy duck parvo novel vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101880651A true CN101880651A (en) | 2010-11-10 |
| CN101880651B CN101880651B (en) | 2012-05-09 |
Family
ID=43052794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010215818 Active CN101880651B (en) | 2010-07-01 | 2010-07-01 | Preparation method of Muscovy duck parvo novel vaccines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101880651B (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102346191A (en) * | 2011-06-17 | 2012-02-08 | 福建省农业科学院畜牧兽医研究所 | Muscovy duck gosling plague latex particle agglutination reagent and preparation method thereof |
| CN102426238A (en) * | 2011-09-07 | 2012-04-25 | 福建省农业科学院畜牧兽医研究所 | Immunofluorescent reagent used for detecting Muscovy duck gosling blast diseases |
| CN102847147A (en) * | 2012-02-24 | 2013-01-02 | 福建省农业科学院畜牧兽医研究所 | Combined live vaccine for muscovy duck parvovirus disease and muscovy duck reovirus disease |
| CN103272230A (en) * | 2012-02-24 | 2013-09-04 | 福建省农业科学院畜牧兽医研究所 | Triple vaccine special for Muscovy duck |
| CN103820397A (en) * | 2014-03-07 | 2014-05-28 | 青岛易邦生物工程有限公司 | Muscovy duck parvovirus and application thereof |
| CN105154410A (en) * | 2015-09-21 | 2015-12-16 | 山东农业大学 | Duck parvovirus strain and live vaccine thereof |
| CN105907728A (en) * | 2016-06-18 | 2016-08-31 | 青岛易邦生物工程有限公司 | Gosling plague virus originated from muscovy ducks |
| CN105920596A (en) * | 2016-06-18 | 2016-09-07 | 青岛易邦生物工程有限公司 | Muscovy duck parvovirus and gosling plague bivalent vaccine |
| CN106075426A (en) * | 2016-06-18 | 2016-11-09 | 青岛易邦生物工程有限公司 | A kind of Goose Parvovirus vaccine |
| CN106620687A (en) * | 2016-11-10 | 2017-05-10 | 刘同明 | Immunization method for gosling plague |
| CN108465107A (en) * | 2018-06-05 | 2018-08-31 | 山东信得科技股份有限公司 | A kind of 2 type adenovirus of duck and Muscovy duck parvovirus disease bivalent inactivated vaccine |
| CN108707588A (en) * | 2018-06-05 | 2018-10-26 | 山东信得科技股份有限公司 | A kind of Muscovy duck parvovirus strain and its application |
| CN112501132A (en) * | 2020-08-28 | 2021-03-16 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | Duck source goose parvovirus artificial attenuated strain and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1426814A (en) * | 2001-12-19 | 2003-07-02 | 福建省农业科学院畜牧兽医研究所 | Foreign duck liver ichthyophthirius active vaccine and its preparation method |
| CN1528454A (en) * | 2001-12-19 | 2004-09-15 | 福建省农业科学院畜牧兽医研究所 | Foreign duck liver ichthyophthirius active vaccine and preparation method thereof |
-
2010
- 2010-07-01 CN CN 201010215818 patent/CN101880651B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1426814A (en) * | 2001-12-19 | 2003-07-02 | 福建省农业科学院畜牧兽医研究所 | Foreign duck liver ichthyophthirius active vaccine and its preparation method |
| CN1528454A (en) * | 2001-12-19 | 2004-09-15 | 福建省农业科学院畜牧兽医研究所 | Foreign duck liver ichthyophthirius active vaccine and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 《中国兽医学报》 19970930 程由铨等 雏番鸭细小病毒病诊断技术和试剂的研究 第434-436页 第17卷, 第5期 2 * |
| 《中国兽医学报》 20030531 陈少莺等 番鸭细小病毒和鹅细小病毒二联弱毒细胞苗的研究 第226-228页 第23卷, 第3期 2 * |
| 《中国预防兽医学报》 20020731 陈少莺等 鹅细小病毒弱毒株选育的研究 第286-288页 第24卷, 第4期 2 * |
| 《福建省农科院学报》 19970630 程由铨等 番鸭细小病毒弱毒疫苗的研究 第31-35页 , 2 * |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102346191B (en) * | 2011-06-17 | 2013-09-11 | 福建省农业科学院畜牧兽医研究所 | Muscovy duck gosling plague latex particle agglutination reagent and preparation method thereof |
| CN102346191A (en) * | 2011-06-17 | 2012-02-08 | 福建省农业科学院畜牧兽医研究所 | Muscovy duck gosling plague latex particle agglutination reagent and preparation method thereof |
| CN102426238A (en) * | 2011-09-07 | 2012-04-25 | 福建省农业科学院畜牧兽医研究所 | Immunofluorescent reagent used for detecting Muscovy duck gosling blast diseases |
| CN102426238B (en) * | 2011-09-07 | 2013-09-04 | 福建省农业科学院畜牧兽医研究所 | Immunofluorescent reagent used for detecting Muscovy duck gosling blast diseases |
| CN103272230B (en) * | 2012-02-24 | 2015-01-28 | 福建省农业科学院畜牧兽医研究所 | Triple vaccine special for Muscovy duck |
| CN102847147A (en) * | 2012-02-24 | 2013-01-02 | 福建省农业科学院畜牧兽医研究所 | Combined live vaccine for muscovy duck parvovirus disease and muscovy duck reovirus disease |
| CN103272230A (en) * | 2012-02-24 | 2013-09-04 | 福建省农业科学院畜牧兽医研究所 | Triple vaccine special for Muscovy duck |
| CN102847147B (en) * | 2012-02-24 | 2014-10-01 | 福建省农业科学院畜牧兽医研究所 | Combined live vaccine for muscovy duck parvovirus disease and muscovy duck reovirus disease |
| CN103820397B (en) * | 2014-03-07 | 2016-05-11 | 青岛易邦生物工程有限公司 | A kind of kind Duck parvovirus and application thereof |
| CN103820397A (en) * | 2014-03-07 | 2014-05-28 | 青岛易邦生物工程有限公司 | Muscovy duck parvovirus and application thereof |
| CN105154410A (en) * | 2015-09-21 | 2015-12-16 | 山东农业大学 | Duck parvovirus strain and live vaccine thereof |
| CN105154410B (en) * | 2015-09-21 | 2018-04-03 | 山东农业大学 | A kind of Duck parvovirus strain and its live vaccine |
| CN105920596A (en) * | 2016-06-18 | 2016-09-07 | 青岛易邦生物工程有限公司 | Muscovy duck parvovirus and gosling plague bivalent vaccine |
| CN106075426A (en) * | 2016-06-18 | 2016-11-09 | 青岛易邦生物工程有限公司 | A kind of Goose Parvovirus vaccine |
| CN105907728A (en) * | 2016-06-18 | 2016-08-31 | 青岛易邦生物工程有限公司 | Gosling plague virus originated from muscovy ducks |
| CN105907728B (en) * | 2016-06-18 | 2019-03-12 | 青岛易邦生物工程有限公司 | A kind of kind duck source Goose Parvovirus |
| CN106075426B (en) * | 2016-06-18 | 2021-02-05 | 青岛易邦生物工程有限公司 | Gosling pestivirus vaccine |
| CN105920596B (en) * | 2016-06-18 | 2021-02-05 | 青岛易邦生物工程有限公司 | Muscovy duck parvovirus disease and gosling plague bivalent vaccine |
| CN106620687A (en) * | 2016-11-10 | 2017-05-10 | 刘同明 | Immunization method for gosling plague |
| CN108465107A (en) * | 2018-06-05 | 2018-08-31 | 山东信得科技股份有限公司 | A kind of 2 type adenovirus of duck and Muscovy duck parvovirus disease bivalent inactivated vaccine |
| CN108707588A (en) * | 2018-06-05 | 2018-10-26 | 山东信得科技股份有限公司 | A kind of Muscovy duck parvovirus strain and its application |
| CN112501132A (en) * | 2020-08-28 | 2021-03-16 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | Duck source goose parvovirus artificial attenuated strain and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101880651B (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101880651B (en) | Preparation method of Muscovy duck parvo novel vaccines | |
| CN102174476B (en) | Inactivated vaccine for preventing duck virus hepatitis and preparation method thereof | |
| CN106497890B (en) | A kind of XF-1 plants of porcine pseudorabies virus variant and preparation method and application | |
| CN102492661B (en) | Preparation method and application of immunization preparation for controlling novel duck reovirus | |
| CN101948809B (en) | Inactivated vaccine for preventing duck viral hepatitis and preparation method thereof | |
| CN104721817B (en) | A kind of vaccine combination and its preparation method and application | |
| CN106267195A (en) | A kind of pig virus diarrhoea triple antigen antibody complex and preparation method thereof | |
| CN103305474A (en) | Porcine pseudorabies virus strain as well as inactivated vaccine and applications thereof | |
| CN108794627A (en) | A kind of preparation method of duck reovirus refined vitelline antibody | |
| CN104258385A (en) | Applications of BHK-21 cell full-suspension culture technology in production of newcastle disease vaccine | |
| CN103143008B (en) | Duck tembusu virus living vaccine and preparation method thereof | |
| CN101099864A (en) | Method for preparing inactivated vaccine both for preventing chicken Newcastle disease and infectious bronchitis | |
| CN104043117B (en) | A kind of vaccine combination and its preparation method and application | |
| CN104338127A (en) | Method for producing inactivated vaccine of H9N2 subtype of avian influenza virus and product of inactivated vaccine | |
| CN103013931B (en) | DHAV (duck hepatitis A virus) JS strain and application of DHAV JS strain in duck virus hepatitis prevention and cure | |
| CN107050448A (en) | A kind of preparation method of avian influenza virus, aviadenovirus bivalent inactivated vaccine | |
| CN103272230A (en) | Triple vaccine special for Muscovy duck | |
| CN101020054B (en) | Inactivated vaccine for preventing and treating paramyxovirus disease of pigeon and its preparation | |
| CN102166355B (en) | Quadruple inactivated vaccine for preventing chicken diseases | |
| CN103864931B (en) | A kind of preparation of pseudoabies standard positive serum and freeze-drying store method thereof | |
| CN103937753A (en) | H9N2 subtype avian influenza virus strain as well as inactivated vaccine and application thereof | |
| CN102727881A (en) | Highly pathogenic porcine reproductive and respiratory syndrome JXAl-R strain- porcine parvovirus disease bigeminal live vaccine and preparation method and application thereof | |
| CN101380470B (en) | Pig parvovirus live vaccine | |
| CN104388396A (en) | Porcine pseudorabies virus strain, inactivated vaccine prepared from porcine pseudorabies virus strain and application of porcine pseudorabies virus strain | |
| CN104195114A (en) | Avian pneumovirus and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |